- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07621627
Peritoneal Transport With a New Bicarbonate-based Peritoneal Dialysis Solution Compared to Conventional Solution.
Study Overview
Status
Detailed Description
Patients treated with peritoneal dialysis (PD)are investigated twice of different days with a single 4h dwell study: once with solution with a solution with bicarbonate 15 mmol/L abd Lactate 15 mmol/L as buffer (Physioneal TM) and once with conventional lactate-buffered (40 mmol/L) PD solution (Dianeal TM). Aproximately 2 liter of PD solution was infused each time. Intraperitoneal fluid was sampled during the dwell at t = 0, 3, 6, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 minutes from the end of the dialysis fluid infusion and the start of the peritoneal dwell. Venous blood samples were drawn from the patient before the start of the dwell and at t = 15, 60, 120, 240 minutes.
New and spent dialysate bags were weighed before and after each dwell to assess infused and drain volumes, respectively; the volumes were adjusted for the weight of the empty bags. Radio-iodinated serum albumin (RISA) added to the solutions before infusion was used as volume marker to estimate intraperitoneal volume. The residual volume (after the previous dwell) was calculated from the dilution of the marker upon infusion of fresh dialysate; after the dwell the peritoneal cavity was rinsed with 1 liter of solution (glucose 1.36%) in order to estimate post-drain residual volume.
Ultrafiltration volume was calculated from the changes in intraperitoneal volume (using 3 minutes after infusion as reference) and corrected for volumes of taken samples. The rate of peritoneal absorption was estimated from the disappearance of the marker from the peritoneal cavity].
The composition of the pre-dialysis (residual) fluid was assessed based on the sample taken from the spent dialysate from the previous dwell.
Concentrations of urea, creatinine, glucose, phosphate, chloride, and lactate, in plasma and dialysate, were measured by Monarch 1000 (Instrumentation Laboratory, MA), while flame photometry was used for sodium and potassium. Dialysate pH was measured with a pH meter. The concentrations of calcium, CO2, bicarbonate, and plasma pH were measured by AVL OMNI Combi Blood Gas Analyzer (AVL, Graz, Austria). The plasma concentrations of glucose, sodium, urea, creatinine, potassium, chloride, and phosphate were corrected for plasma water fraction. Creatinine measurements in dialysate were corrected for glucose concentration. Albumin and beta-2 microglobulin (B2M) concentration were measured with immunological methods.
Advanced mathematical modelling is used to analyze the results and tgo asses transport parameters.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, S-141 86
- Research unit, renal medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patient treated with peritoneal dialysis in a clinically stable condition
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Bicarbonate lactate solution investigatd first
The patients were studied with the bicarbonate-lactate solution the first study day and with conventional lactate.based
solution on a later day.
|
All patients were studied twice with a 4-h dwell study (one peritoneal dialysis dwell) about 7 days apart.
The two arms represent different order of the used periteonal dialysis fluid for the two dwell studies.
|
|
Experimental: Lactate solution investigated first
The patients were studied with the conventional lactate.based
solution the first study day and with bicarbonate-lactate solution on a later day.
|
All patients were studied twice with a 4-h dwell study (one peritoneal dialysis dwell) about 7 days apart.
The two arms represent different order of the used periteonal dialysis fluid for the two dwell studies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in net ultrafiltration (ml)
Time Frame: 4 hours
|
Assessment of fluid transport during a PD dwell.
Intraperitoenal volume changes during the 4 hour dwells will be assesed from dilution of the added volume marker with correction for absorption of the marker.
Amount of marker remaining in the drained fluid after four hours will be subratcted from the initial added amount to calculate amount of marker absorbed during the dwell.
Residual volumes before and after the dwell can also be calculated from dilution of the marker.
This makes it possible to calculate the intraperitoneal volume of time curve during the dwell and net ultrafiltration (=net fluid removal).
To simplify, the intraperitoneal volume (ml) at 240 minutes of the dwell minus the intraperitoneal volume after infusion of the dialysis fluid.
|
4 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes to acid-base homeostasis
Time Frame: 4 hours
|
Assessment of pH, concentrationa of bicarbonate and lactate i dialysate and plasma.
Frequent dialysate sampling will be used and plasma levels will be assessed mutiple times.
For each solute, the mass removed/absorbed will be calculated as the difference between the dialysate mass the end of the dwell (dialysate concentration times dialysate volume, corrected for total volume of samples) and mass immediately after infusion of fresh dialysate.
The latter is calculated adding up the mass in residual and infused fluids.
As the conventional lactate-buffered solution is acidic (pH 5.3) and the bicarbonate-lactate buffered solution is neutral (pH 7.4) the difference in pH between the solutions over time of the dwell may be described.
|
4 hours
|
|
Differences in small solute transport
Time Frame: 4 hours
|
Frequent dialysate sampling will be used and plasma levels will be assessed mutiple times for several small solutes.
For each solute, the mass removed/absorbed will be calculated as the difference between the dialysate mass the end of the dwell (dialysate concentration times dialysate volume, corrected for total volume of samples) and mass immediately after infusion of fresh dialysate.
The latter is calculated adding up the mass in residual and infused fluids.
As the conventional lactate-buffered solution is acidic (pH 5.3) and the bicarbonate-lactate buffered solution is neutral (pH 7.4) it makes it possible to assess if pH affects transport characteristics of other solutes, in particular small solutes (Na, K, Ca, bicarbonate, lactate, creatinine, urea).
|
4 hours
|
|
Differences in protein transport
Time Frame: 4 hours
|
Frequent dialysate sampling will be used and plasma levels will be assessed mutiple times for several small solutes.
For each solute, the mass removed/absorbed will be calculated as the difference between the dialysate mass the end of the dwell (dialysate concentration times dialysate volume, corrected for total volume of samples) and mass immediately after infusion of fresh dialysate.
The latter is calculated adding up the mass in residual and infused fluids.
As the conventional lactate-buffered solution is acidic (pH 5.3) and the bicarbonate-lactate buffered solution is neutral (pH 7.4) it makes it possible to assess if pH affects transport characteristics of proteins (albumin and beta-2-microglobuline).
|
4 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Pathological Conditions, Signs and Symptoms
- Kidney Failure, Chronic
Other Study ID Numbers
- Dnr 283/96
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dialysis Dependent Chronic Kidney Disease
-
Pharmacosmos A/SCompletedNon-dialysis Dependent Chronic Kidney Disease
-
Pharmacosmos A/SCompletedChronic Kidney Disease Stage 5 (Dialysis Dependent)India
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Active, not recruitingNon-Dialysis-Dependent Chronic Kidney DiseaseChina
-
Akebia TherapeuticsCompletedAnemia | Dialysis-dependent Chronic Kidney DiseaseUnited States
-
Gødstrup HospitalNot yet recruitingHigh Blood Pressure | Sodium Excess | Dialysis Dependent Chronic Kidney Disease | Dialysis PatientsDenmark
-
Akebia TherapeuticsCompletedAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
-
Akebia TherapeuticsCompletedAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States, Italy, Korea, Republic of, Portugal, Russian Federation, Ukraine, Poland, Argentina, Brazil, Germany, Mexico
-
Akebia TherapeuticsTerminatedAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States
-
Akebia TherapeuticsWithdrawnAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States
-
Akebia TherapeuticsCompletedAnemia | Non-Dialysis-Dependent Chronic Kidney DiseaseUnited States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more